InvestAcure

InvestAcure - a community of spare change investors powering the search for a cure!

Alzheimer's afflicts 50 million worldwide and 26% or 65 million American adults have a relative with the disease. Yet, companies spearheading the search for a cure have difficulty securing investment for clinical trials, stifling progress. InvestAcure enables those impacted by Alzheimer's to partner in the search for a cure by rounding-up day-to-day transactions and investing the spare change in clinical stage pharmaceuticals working on promising drugs. This helps transition investment leadership from a narrow group of high-risk investors to a much larger and stable investment base, leading to more clinical trials, more drugs and drug combinations tested and progress to a cure. If just 1.5% of the 70 million directly impacted by Alzheimer's become spare change investors, that would add up to $50 million per month or $3 billion over 5 years. That's enough investment to fund 240 Phase 2 clinical trials, and would have 30X the impact of Bill Gates's $100 million proposed Alzheimer's foundation and VC fund.  Our business model: The InvestAcure business model is that of an internet-based RIA/Broker-dealer, similar to Acorns, Stash and Betterment. Our plan is to charge a management fee of $1 p/month and transaction fees TBD, possibly up to another $1 p/month. We also plan to launch a BDC to allow investment in private companies and provide companies with guidance on research. How it works: • Each individual sets up their own investment account and links the credit cards they use for daily transactions. • Using a commonly available and secure application, InvestAcure would periodically calculate the round-ups from day-to-day transactions and transfer the appropriate amount to be invested. • Investments would be guided by a team of leading Alzheimer's scientists based on the scientific promise of the research conducted by each company. • Our scientists would also provide users with important updates on clinical trials and progress towards a cure, making them feel like partners in the process. Management team: Max Tokarsky, our CEO is a social entrepreneur who built RAJE, a large educational non-profit and had the idea for InvestAcure when his daughter was battling cancer. Lawrence Pine, with an MBA and background in IT, our COO worked with Max as the COO of RAJE and joined him in co-founding the new company. Paul Son, our head of UX/UI development, was Project Manager, Tech Engineer & UX Designer at Citygames, Count.it, TruOptik. Alex Geis, our Lead Tech Advisor, founded 21Productions, licensed software to leading universities and is CTO at TruOptik. Scientific advisory board: Dr. George Perry, Editor-in-Chief of Journal of Alzheimer's, Dean UT-San Antonio, one of the top most-cited scientists in Neuroscience. Dr. Hugo Geerts, is CSO of In Silico Biosciences, headed Johnson & Johnson Alzheimer’s research and developed one of only 5 approved Alzheimer’s drugs. Dr. Adeboye Adejare, serves on national panels including NIH and Alzheimer’s Association. His efforts have resulted in over 50 publications, 5 patents, and more than 100 presentations at national and international conferences.